A phase II trial of neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer - OGSG1902

GOTO Masahiro0 个研究点目标入组 46 人开始时间: 2019年10月11日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Histological proven adenocarcinoma
•2) Borrmann type 4 or large (8cm or more by Enhanced abdominal CT or gastrointestinal endoscopy) type 3
•3) No peritoneal metastasis (CY0 or CY1, and P0) by laparoscopy and CT within 28days.No sign of distant metastasis including liver metastasis or paraaortic lymph node metastasis
•4) Length of esophageal invasion less or equal to 3cm by image examination within 28 days
•5) Age between 20 and 80 at registration
•6) Performance Status(ECOG):0,1
•7) No prior treatment of chemotherapy or radiation therapy
•8) Adequate organ function
•9) Fair oral intake with or without bypass surgery
•10) HER2 negative or not examined
•11) Written informed consent from patient

•1) Synchronous or metachronous (within 5 years) malignancies
•2) Infectious disease requiring systemic treatment(over 38 degrees Celsius)
•3) During pregnancy, postparturition, or during lactation
•4) Severe mental disease
•5) History of unstable angina pectoris within three weeks or myocardial infarction within six months before registration
•6) Receiving continuous systemic corticosteroid or immunosuppressant treatment
•7) Under treatment with flucytosine, phenytoin, or warfarin
•8) Poorly controlled valve disease, dilated or hypertrophic cardiomyopathy
•9) HBs antigen positive
•10) Interstitial pneumonia, pulmonary fibrosis, or severe emphysema based on chest CT
•11) Poorly controlled hypertension or diabetes
•12) Patients judged inappropriate for the study by thephysicians

发起方

GOTO Masahiro